Preclinical trials in mouse models of APL

Slides:

Advertisements

Similar presentations

Retinoic Acid Receptor- Alpha and Its Role in Acute Promyelocytic Leukemia By Alex Sheng.

Advertisements

Retinoic Acid Receptor Alpha (RARα) Acute Promyelocytic Leukemia (APL)

Retinoic Acid Receptor Alpha and Acute Promyelocytic Leukemia Nidhi Thapar April 1, 2004.

Bench to Bedside Translation Patient Derived Xenograft (PDX) Models and Case Study S. S. Gail Eckhardt, M.D. University of Colorado Cancer Center September.

Brent Hoffman. HOXA9 is one of the HOX transcription factors regulating Anterior to Posterior patterning in early development.

Acute promyelocytic leukemia (APL) From the worst to the best prognosis MUDr. Petr Pavlíček Internal Hematological Clinics FNKV and 3LF UK in Prague.

Are all APL screated equal? Background image removed due to copyright considerations.

Retinoic Acid Receptor α Acute Promyelocytic Leukemia Michi Nair.

Ashkan Emadi 1, Steven D. Gore Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, United States Blood Reviews 24 (2010)

What's New in Basal Insulin for Diabetes

Table 1. The French-American-British (FAB) classification of AML

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

Role of Chemotherapy in the Current Treatment Paradigm for Men With CRPC.

EBV DNA: a Hodgkin lymphoma biomarker?

Frequent mutations in the ligand-binding domain of PML-RARα after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship.

PARPi combinations against HR-proficient tumors.

Early studies evaluating role of immune infiltrate in colorectal cancer

by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle

Figure 3 Drug cycling with collateral sensitivity

Lessons taught by acute promyelocytic leukemia cure

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

10.3 Regulation I. Controls A. Cell growth & division depend on protein signals & other environmental signals II. Checkpoints B. Feedback.

Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure

Precision Medicine A New Era Hazem Assi American University of Beirut

High-throughput combination drug screening to nominate potent drug combinations. High-throughput combination drug screening to nominate potent drug combinations.

Treatment with MI-773 causes changes in p53 status.

Effect of MI-773 and/or cisplatin in a preclinical model of ACC

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis Russell F. Jacoby, Carolyn E.

Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.

Maria Hodges, Catherine Tissot, Kathy Howe, David Grimwade, Paul S

GS87 demonstrates efficacy in a circulating AML mouse model system.

A, Top inhibitors of Ba/F3 transformed with CD74–ROS1, color coded by clinical development status: FDA-approved (green), phase III (yellow), phase II (blue),

Protein expression profile in a dasatinib-resistant cell line.

The Pathway to Progress Against Chronic Myelogenous Leukemia.

Analysis of thermal stability and aggregation properties before and after disulfide stabilization of the pMHCI complex. Analysis of thermal stability and.

Saturation analysis and the discovery of actionability of mutational hotspots. Saturation analysis and the discovery of actionability of mutational hotspots.

Antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against xenograft models sensitive.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

Xenograft regrowth studies.

Location of common clinically relevant mutations in EGFR

Association between BRCA1 transcript level and cisplatin sensitivity, BRCA1 promoter methylation, and NtAI. Association between BRCA1 transcript level.

SY-1425 induces maturation in RARA-high AML

The Tribble with APL: A New Road to Therapy

SY-1425 shows similar response in RARA-high AML cell lines to APL

Tivantinib behaves as an antimitotic agent.

Dasatinib overcomes the growth and metastatic spread of vemurafenib-resistant tumors. Dasatinib overcomes the growth and metastatic spread of vemurafenib-resistant.

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

The efficacy of telomerase inhibition–based therapies, such as imetelstat, depends on the tumor telomere length at the beginning of treatment. The efficacy.

Change in FES uptake in the tumor during fulvestrant treatment.

CPI-444 enhances T-cell activation in MC38 tumors.

Combined inhibition of coamplified RTKs is required for response.

Possible outcomes of therapeutic treatments using the spiral model.

Wild-type mice weight following 6-thio-dG and 6-thioguanine treatment.

Targeted compounds exhibit cancer-selective ex vivo drug responses in AML. A, waterfall plot that highlights the most potent cancer-selective drugs for.

Metastatic signals respond to castration.

A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.

Survival, subsequent therapies, and response.

Response to crizotinib in an 8-year-old boy with refractory IMT harboring a TFG–ROS1 fusion. Response to crizotinib in an 8-year-old boy with refractory.

Crizotinib-resistant NPM-ALK mutants retain sensitivity to ganetespib.

One potential implementation for the use of outlier kinase profiling and targeting for clinical management of pancreatic cancer in a precision medicine.

Chemopreventive effect of bexarotene and budesonide on mouse SCLC

Regulation of signaling by wild-type and oncogenic Ras.

In vivo efficacy of JAK inhibition in transformed Pax5+/− pro-B cells harboring Jak3V670A. In vivo efficacy of JAK inhibition in transformed Pax5+/− pro-B.

Curative effect of W+T treatment in vivo.

Greater influx of PMNs and ST using PEGPH20/shIDO-ST.

Genotype-specific combinatorial drug sensitivities in melanoma.

Presentation transcript:

Preclinical trials in mouse models of APL Preclinical trials in mouse models of APL. A, mouse models of APL respond differentially to As2O3. Preclinical trials in mouse models of APL. A, mouse models of APL respond differentially to As2O3. PLZF-RARα leukemia proved resistant to therapy as it was resistant to RA as single agent. By contrast, PML-RARα leukemia proved exquisitely sensitive to As2O3, which triggers the degradation of the fusion protein, suggesting that this drug could be used successfully in large-scale clinical trials. B, treatment of PML-RARα mice with RA and As2O3 in combination leads to a longer lasting remission compared to the treatment with As2O3 alone. Blue, sick; purple, healthy. Caterina Nardella et al. Cancer Discovery 2011;1:108-116 ©2011 by American Association for Cancer Research